IPO Issue Details
Issue Price / Price Band₹1,083 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size13 Shares per Lot
Total Issue Size46,16,804 shares (aggregating up to ₹500.00 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenFri, 16 Jul 2021
Subscription CloseTue, 20 Jul 2021
Anchor AllotmentThu, 15 Jul 2021
Basis of AllotmentMon, 26 Jul 2021
Initiation of RefundsTue, 27 Jul 2021
Credit of Shares to DematWed, 28 Jul 2021
Listing DateThu, 29 Jul 2021
UPI Mandate Deadline2021-07-20
Application & Investment Details
Retail — Min (1 Lots)₹14,079 — 13 shares
Retail — Max (13 Lots)₹183,027 (13 Lots)
HNI — Min (15 Lots)₹2,11,185 — 195 shares
Pre-IPO Promoter Holding2,00,87,500 shares
Post-IPO Promoter Holding2,21,65,062 shares
Fresh Issue Shares20,77,562 shares (aggregating up to ₹225.00 Cr)
Offer for Sale Shares25,39,242 shares of ₹10 (aggregating up to ₹275.00 Cr)
About Tatva Chintan Pharma Chem Ltd.
Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals. It is among the largest manufacturer of SDAs for zeolites in India.The company serves customers across industries i.e. automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical, personal care, and others. Its products are not only sold in India but also export to 25+ countries all over the world such as the USA, Germany, South Africa, China, and the UK. In FY 2020, total export contributed to 76% of total revenue from operations.Merck, Bayer AG, Ipox Chemicals, Laurus labs, Navin Fluorine International Limited, Atul Limited, Otsuka Chemicals, SRF Limited, Hawks Chemical Company, Firmenich Aromatics Prod Pvt Ltd, and Divi's laboratories are a few of customers of the company. Currently, it has two manufacturing facilities at Ankleshwar and Dahej in Gujarat.Competitive strengthsLeading manufacturer of structure directing agents and phase transfer catalyst.Diversified product portfolio.Global market presence with customer base across industries.Strategically located manufacturing facility in Gujarat with close proximity to Hazira Port.Experienced promoters and managers team.Strong financial performance track record.
Objects of the Issue
Tatva Chintan Pharma Chem Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility
147.10
2
2 Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara; and
23.97
3
3 General corporate purposes
36.21
Shareholding & Lock-in
Pre-IPO Promoter Holding
2,00,87,500 shares
Post-IPO Promoter Holding
2,21,65,062 shares
Lock-in Period (30%)August 25, 2021
Lock-in Period (50%)October 24, 2021